Hint mode is switched on Switch off
For swift navigation between sections

CervoMed
LEI 549300I3DV7F8OXPNA12

PDF download

Choose all Reset all
Download Cancel
Organization name
CervoMed Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

CervoMed Inc is a clinical stage biotechnology company.

Awards

News

14/07/2026 CervoMed: Regulation Fd Disclosure, The Information Set Forth In The First And Third Paragraphs Of, And Under The Headings “analyses Reinforce Observed Treatment Effect Of Neflamapimod In ‘pure’ Dlb And Support Planned Phase 3 Dose” And “neflamapimod Demonstrated Durable Slowing Of Basal Forebrain Atrophy,” And In The First, Second, Third, Fourth, And Sixth Paragraphs Under The Heading “new Pkpd Analysis And Phase 2 Study Results For Neflamapimod 80 Mg Bid In Dlb Strengthen Understanding Of Dosing” In, The Company’s Press Release Issued On July 14, 2026, Is Incorporated By Reference Into This Item 8.01 Of This Currentreportonform8k, Financial Statements And Exhibits
09/07/2026 CervoMed: Regulation Fd Disclosure, The Information Set Forth In The First And Third Paragraphs Of, And Under The Headings “recent Nature Neuroscience Publication Supports Inhibition Of P38α As Potential Therapeutic Approach In Ftd,” And “interim Results From The Phase 2a Clinical Trial To Be Presented At Ctad” In, The Company’s Press Release Issued On July 9, 2026, Is Incorporated By Reference Into This Item 8.01 Of This Currentreportonform8k, Financial Statements And Exhibits
18/06/2026 CervoMed: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits
16/06/2026 CervoMed: Other Events, Financial Statements And Exhibits
09/06/2026 CervoMed: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300I3DV7F8OXPNA12
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001053691
  • EIN
    30-0645032
Registration is required to get access.